60 Degrees Pharmaceuticals, Inc. has taken a significant step to enhance its financial position by entering into inducement agreements with certain holders of existing warrants. This move allows the company to raise funds while providing an incentive for warrant holders to exercise their options at a reduced price.

On November 5, 2026, the company announced that it had signed inducement offer letter agreements with holders of warrants originally issued between 2024 and 2025. The existing warrants allow the purchase of up to 584,492 shares of common stock at exercise prices ranging from $7.60 to $27.60 per share. Under the new agreements, holders will exercise these warrants for cash at a significantly reduced price of $0.90 per share.

This strategic maneuver is expected to generate approximately $526,042.80 in gross proceeds for the company, which will be allocated towards working capital and general corporate purposes. The company anticipates closing these transactions around November 9, 2026, pending customary closing conditions.

Background

60 Degrees Pharmaceuticals, Inc. operates in the pharmaceutical preparations sector, specifically under the SIC code 2834. The company is listed on the Nasdaq exchange under the ticker symbols SXTP and SXTPW. As an emerging growth company, 60 Degrees Pharmaceuticals has been actively seeking ways to strengthen its financial footing amidst a competitive landscape.

What the Filing Says

According to the SEC filing, the inducement letters stipulate that the holders will exercise their existing warrants in exchange for new unregistered warrants to purchase an additional 1,168,984 shares of common stock. This issuance represents 200% of the existing shares being exercised. The new warrants will have an exercise price of $0.90 per share and will be subject to stockholder approval.

The filing states, "The Company expects to receive aggregate gross proceeds of $526,042.80 from the exercise of the Existing Warrants, before deducting placement agent fees and other offering expenses payable by the Company." This indicates a clear financial strategy aimed at leveraging existing assets for immediate capital.

Impact

This development may affect various stakeholders, including existing shareholders, potential investors, and competitors within the pharmaceutical preparations industry. The decision to reduce the exercise price of the warrants could lead to increased shareholder engagement and provide a short-term liquidity boost for the company.

What's Next

The company plans to file a registration statement for the resale of the new warrant shares within 30 days of the inducement letters. Additionally, a stockholder meeting will be held within 90 days to seek approval for the issuance of the new warrants. If approval is not obtained, the company will continue to call meetings every 90 days until the approval is secured or the warrants are no longer outstanding.

Overall, this strategic financial maneuver by 60 Degrees Pharmaceuticals demonstrates a proactive approach to capital management, which may influence similar actions within the pharmaceutical industry as companies navigate their financial landscapes.